Facebook Twitter Instagram You Tube Pinterest LinkedIn RSS Podcasts Video Library Blog
 - Northwestern Memorial Hospital - Chicago

Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Living Donor Liver Transplantation

The A2ALL LADR Protocol: Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Living Donor Liver Transplantation (sub-study to main A2ALL study)

Purpose:

The purpose of this study is to learn if pre-liver transplant treatment using peginterferon plus ribavirin will clear HCV RNA from the blood in HCV-infected recipients, and reduce the risk of recurrent HCV and re-infection of the new liver with hepatitis following liver transplant.

Patients awaiting deceased donor liver transplant will be asked to enroll in this protocol at the time of identification of a potential living liver donor. This study involves about nine centers in the United States and will be enrolling 150 patients in this study over a four-year period.

Inclusion Criteria:

  • Adult (18 years of age or older)
  • LDLT candidate
  • HCV RNA positive
  • Expected time on treatment is at least 12 weeks

Sponsor:

NIH/Schering-Plough/Ortho-Biotech

Principle Investigator:

Laura Kulik, MD 

Cost:

None

IRB Project Number:

1530-002

Contact:

Patrice Al-Saden, RN
312-503-1058

Last UpdateMarch 25, 2011
top